Categories: News

Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023

MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2023 after the market close on Monday, August 7th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com

Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com

Staff

Recent Posts

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…

13 hours ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…

13 hours ago

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

1 day ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

2 days ago

Genesis Healthcare Remains Committed to Securing Longterm Stability

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process…

2 days ago